Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiddo J L Heerspink

Showing results (1-10 of 521) with videos related to

Pageof 53
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 22, 2019
Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidneyHiddo J L Heerspink
The Lancet. Diabetes & Endocrinology|May 4, 2019
Predicting individual treatment response in diabetesHiddo J L Heerspink
Cell Metabolism|March 10, 2021
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitorsTaha Sen, Hiddo J L Heerspink
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 23, 2025
What are the right endpoints to assess the effectiveness of new treatments for IgAN?Niels Jongs, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|June 8, 2026
Authors' Reply: Clarifying Crossover Interpretation and Volume-Signal Assessment in ASSISTAmy Mottl, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|February 26, 2025
Authors' Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?Jianghua Chen, Hiddo J L Heerspink
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2018
Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing PlatformHiddo J L Heerspink, Vlado Perkovic
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2024
Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?Niels Jongs, Hiddo J L Heerspink
The Lancet Regional Health. Europe|July 5, 2022
Progress and opportunities in measuring the burden of Chronic Kidney DiseasePriya Vart, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|September 9, 2024
Clinical Trials for Kidney Disease in the Era of Personalized MedicineHiddo J L Heerspink, Matthias Kretzler
Pageof 53

Showing results (1-10 of 521) with videos related to

Sort By:
Pageof 53
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 22, 2019
Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidneyHiddo J L Heerspink
The Lancet. Diabetes & Endocrinology|May 4, 2019
Predicting individual treatment response in diabetesHiddo J L Heerspink
Cell Metabolism|March 10, 2021
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitorsTaha Sen, Hiddo J L Heerspink
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 23, 2025
What are the right endpoints to assess the effectiveness of new treatments for IgAN?Niels Jongs, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|June 8, 2026
Authors' Reply: Clarifying Crossover Interpretation and Volume-Signal Assessment in ASSISTAmy Mottl, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|February 26, 2025
Authors' Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?Jianghua Chen, Hiddo J L Heerspink
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2018
Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing PlatformHiddo J L Heerspink, Vlado Perkovic
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2024
Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?Niels Jongs, Hiddo J L Heerspink
The Lancet Regional Health. Europe|July 5, 2022
Progress and opportunities in measuring the burden of Chronic Kidney DiseasePriya Vart, Hiddo J L Heerspink
Journal of the American Society of Nephrology : JASN|September 9, 2024
Clinical Trials for Kidney Disease in the Era of Personalized MedicineHiddo J L Heerspink, Matthias Kretzler
Pageof 53